Novavax (NASDAQ:NVAX) PT Lowered to $25.00 at Jefferies Financial Group

Novavax (NASDAQ:NVAX - Free Report) had its price target reduced by Jefferies Financial Group from $31.00 to $25.00 in a report released on Wednesday, Benzinga reports. Jefferies Financial Group currently has a buy rating on the biopharmaceutical company's stock.

Several other research firms have also weighed in on NVAX. JPMorgan Chase & Co. upped their target price on shares of Novavax from $8.00 to $9.00 and gave the stock an "underweight" rating in a report on Monday, August 12th. B. Riley reaffirmed a "buy" rating and set a $26.00 price objective (up from $23.00) on shares of Novavax in a research note on Thursday, October 10th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $17.83.

Novavax Stock Down 19.4 %

Novavax stock traded down $2.45 on Wednesday, hitting $10.15. The company's stock had a trading volume of 32,299,298 shares, compared to its average volume of 10,217,266. Novavax has a one year low of $3.53 and a one year high of $23.86. The firm has a market cap of $1.43 billion, a P/E ratio of -3.20 and a beta of 2.04. The company has a fifty day moving average price of $12.51 and a 200-day moving average price of $11.68.

Novavax (NASDAQ:NVAX - Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.99 earnings per share for the quarter, missing analysts' consensus estimates of $1.82 by ($0.83). The company had revenue of $415.50 million for the quarter, compared to analyst estimates of $458.57 million. The firm's revenue for the quarter was down 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.58 earnings per share. Analysts anticipate that Novavax will post -0.97 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. TSP Capital Management Group LLC lifted its position in shares of Novavax by 23.9% in the first quarter. TSP Capital Management Group LLC now owns 1,376,950 shares of the biopharmaceutical company's stock valued at $6,582,000 after buying an additional 265,250 shares during the last quarter. Swiss National Bank boosted its position in Novavax by 17.1% during the first quarter. Swiss National Bank now owns 211,000 shares of the biopharmaceutical company's stock worth $1,009,000 after purchasing an additional 30,800 shares during the period. Susquehanna Fundamental Investments LLC acquired a new position in shares of Novavax in the first quarter valued at $1,499,000. Headlands Technologies LLC raised its position in shares of Novavax by 1,084.0% in the first quarter. Headlands Technologies LLC now owns 55,137 shares of the biopharmaceutical company's stock valued at $264,000 after purchasing an additional 50,480 shares during the period. Finally, ProShare Advisors LLC lifted its stake in shares of Novavax by 29.9% during the 1st quarter. ProShare Advisors LLC now owns 37,203 shares of the biopharmaceutical company's stock worth $178,000 after buying an additional 8,570 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.